On February 14, 2019, both class action and personal injury cases involving contaminated valsartan-containing drugs were consolidated into a multi-district litigation (MDL) in the District of New Jersey before the Honorable Robert B. Kugler.
Valsartan is a medication prescribed to treat high blood pressure and related conditions. Recent investigations by the FDA revealed that pills distributed by at least four Active Pharmaceutical Ingredient (API) manufacturers were contaminated with carcinogenic substances, called NDMA and NDEA. As a result, both the US FDA and the European Medicines Agency (among other foreign regulatory agencies) predicted that some consumers who took these contaminated pills for a number of years will get cancer.
This MDL will be comprised of both personal injury cases, as well as class actions. As of the time the Judicial Panel on Multidistrict Litigation (JPML) issued its order creating the MDL, there were approximately 40 cases filed. The MDL includes all manufacturers of the recalled valsartan. For a list of these manufacturers, visit the FDA’s website.
The JPML determined that New Jersey was an appropriate venue for the litigation, primarily because many defendants have headquarters in New Jersey, and it is likely that both relevant documents and witnesses will be located in New Jersey as well. Further, Judge Kugler previously presided over a litigation involving a different ARB drug, olmesartan (Benicar).
There is currently no decision on whether other angiotensin II receptor blockers (ARBs), such as irbesartan and losartan, will be included in this MDL.
GoldenbergLaw is currently accepting valsartan, losartan, and irbesartan cases. To learn more about this litigation, please visit our valsartan page. You can also find out whether your medication has been recalled by visiting the FDA’s website. If you or a loved one took one of these drugs and contracted liver, colorectal, stomach, intestinal, kidney, and pancreatic cancer, please contact us. We deliver the gold standard advocacy you deserve.